Navigation Links
LearnSomething, Inc. Announces New Relationship With ASHP
Date:9/28/2010

TALLAHASSEE, Fla., Sept. 28 /PRNewswire/ -- LearnSomething, Inc., a leading provider of e-learning solutions to associations, has announced a new relationship with the American Society of Health-System Pharmacists (ASHP). One of LearnSomething's learning management systems (LMS), Isoph Blue, will be implemented to support ASHP's ongoing learning initiatives.

Carol Wolfe, ASHP's Vice President of Publications and Drug Information, says, "We are excited to be working with LearnSomething. The implementation of the Isoph Blue LMS from LearnSomething will allow ASHP to expand continuing education and competency assessment opportunities for our members, as well as all pharmacists and pharmacy technicians working in hospitals, long-term care, home care, and other health system settings."

Isoph Blue is a customizable portal environment with tools for creating a wide range of learning content and managing a community of learners. It enables organizations to develop and manage a variety of continuing education, training and certification initiatives.

"We are pleased that ASHP has allowed us the opportunity to support their short- and long-term e-learning plans," says LearnSomething's Mark Lambertson, Senior Vice President of Association Sales. "A sophisticated credit management system, reporting tools and integrated marketing options are key components of the Isoph Blue application that ASHP will use to expand their e-learning strategy."

About LearnSomething

LearnSomething has developed innovative e-learning solutions for associations since 1998. Our flexible learning management solutions and services support associations in delivering and tracking continuing education online. Collaborative relationships with leading vendors have provided LearnSomething with unparalleled experience in AMS integration. We deliver solutions to nearly 100 associations and over two million continuing education learning events annually.

Abo
'/>"/>

SOURCE LearnSomething, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ... and full year of its fiscal year ended ... Executive Officer of Array, noted, "Binimetinib and encorafenib, two ... track for regulatory submissions in 2016. Additional data ... BRAF-mutant colorectal cancer further validate the value of ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... Biosafety , , , ... June 29 Remember chemistry sets, ham radio, amateur astronomy, and early ... around the world belong to the Do-It-Yourself Biology (DIYbio) community, working on everything ... treatments for diseases. , , , ...
... Ireland , June 28 Warner Chilcott plc ... IV Certification Notice from Par Pharmaceutical, Inc. ("Par").  The Paragraph IV Certification ... Application (ANDA) by Par for a generic version of the Company,s ASACOL ... , , ...
Cached Medicine Technology:Responsible Science for Do-It-Yourself Biologists 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 3
(Date:8/3/2015)... ... August 03, 2015 , ... Foot and Ankle ... new associate podiatrist, creating the largest medical practice in the Mid-Atlantic region – and ... FASMA operates 21 locations with 33 doctors. , Dr. Hetal Kathrotiya-Mago is a Maryland ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Did you know ... Orange County looking for exceptional and affordable home care options which A-1 Home Care ... just a few of the credentials A-1 Home Care Agency is known ...
(Date:8/2/2015)... (PRWEB) , ... August 03, 2015 , ... A new ... of some childhood cancers. The study is led by Kenneth G. Lucas, M.D. ... University of Louisville in collaboration with colleagues at Kosair Children’s Hospital and ...
(Date:8/2/2015)... ... , ... Molecular biologists in New South Wales say a protein linked to ... posted an article on the new research. Click here to read it now. ... in tissue samples from 42 patients with peritoneal mesothelioma and found a direct correlation ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... are in “a trending profession” that comprises a growing percentage of U.S. physicians, ... most. , That was one part of the message delivered by John W. ...
Breaking Medicine News(10 mins):Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5
... de Toulouse-Lautrec suffered, is a genetic disease characterized by ... into how joints are destroyed by arthritis. It is ... K which hampers osteoclasts (the cells that break down ... bone resorption and dense, brittle bones. , Cathepsin ...
... Patients Received Assistance with Drug Co-Pays, HOUSTON, Nov. ... a national oral oncology specialty pharmacy, has,exceeded the $10 ... co-pays since the launch of Care Advantage in August ... Advantage to be able to,increase patient access to oral ...
... 4 Mylan Inc. (NYSE: MYL ),today ... approval from the U.S. Food and Drug Administration ... Levetiracetam Tablets, 250 mg,500 mg and 750 mg. ... Keppra(R)., Robert J. Coury, Mylan,s Vice Chairman ...
... blood pressure experienced during pregnancy could be a woman,s ... heart disease the number one killer of Canadian ... Gynecology, Graeme Smith. , Called pre-eclampsia, this type ... of all pregnancies. , But because most practicing ...
... , , TUESDAY, Nov. 4 (HealthDay News) -- Children who live ... undernourished, a new study finds. , The same is true ... impact the most, said study author Dr. Michael Weitzman, chairman ... "We know that there are long-term consequences of food insecurity ...
... Secretary and other members of bipartisan,group of Capitol ... energy, transportation, trade, labor and employment,and tax policy, ... and grueling,Presidential campaign, one thing is certain: change ... with or regulated by the federal government,will face ...
Cached Medicine News:Health News:Genetic disorder sheds light on enzyme's role in bone metabolism 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3Health News:Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately 2Health News:Pregnancy disorder signals need to screen for heart disease 2Health News:Smokers' Homes More Likely to House Hungry Kids 2Health News:Smokers' Homes More Likely to House Hungry Kids 3Health News:Venable's 'Election Watch Group' Assesses Presidential Election's Impact on Multiple Industries 2Health News:Venable's 'Election Watch Group' Assesses Presidential Election's Impact on Multiple Industries 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: